LAS VEGAS, NEVADA / ACCESS Newswire / February 13, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a leading fintech company specializing in next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and the safekeeping of digital assets, is proud to announce its nomination for the SiGMABest Online Payment Services 2025 award. This recognition coincides with ALT5 Sigma's participation in SiGMA Eurasia, one of the world's premier fintech and blockchain conferences, set to take place in Dubai on February 23-25, 2025.
ALT5 Sigma will be exhibiting at the three-day event, held at Dubai Festival City - Festival Arena. Attendees are invited to visit booth #101G, starting February 24 for live product demonstrations, to explore advanced payment solutions, and to learn more about the company's cutting-edge technologies.
The Dubai conference will focus on groundbreaking technologies, including blockchain, AI, fintech, IoT, quantum computing, and big data. With influential speakers, distinguished guests, and key government officials in attendance, Dubai continues to affirm its commitment to being at the forefront of technological advancement. As a hub for pioneering innovators, visionary business leaders, and elite thinkers, the city plays a pivotal role in shaping the future of the MENA region and transforming ambitious business aspirations into monumental successes.
"We are honored to be nominated for this prestigious award, which recognizes ALT5 Sigma's role in empowering digital transformation," said Peter Tassiopoulos, CEO of ALT5 Sigma Corporation. "Following a successful and transformative 2024, we remain focused on expanding our revenue and accelerating the adoption of our technologies across key industries, including gaming. The gaming sector has historically been a driver of technological innovation, and we look forward to engaging with both new and existing customers to showcase our crypto payment solutions."
About ALT5 Sigma Corporation
ALT5 Sigma Corporation (Nasdaq:ALTS) is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.
Launched in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime." ALT5 Sigma Inc. processed over $2 billion USD in cryptocurrency transactions in 2024.
ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions'NYFIX gateway for approved customers.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also may contain statements or links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Contact Information
Media/Investor Relations
ir@alt5sigma.com
1-800-400-2247
SOURCE: ALT5 Sigma Corp.
View the original
press release on ACCESS Newswire
